Midostaurin

Back to search

Molecule Structure

Scientific Name

Midostaurin

Description of the Drug

Midostaurin is an antineoplastic agent used to treat high-risk acute myeloid leukemia (AML) with specific mutations, aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematologic neoplasm (SM-AHN), or mast cell leukemia (MCL).

Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB06595

Brand Name(s)

Rydapt

Company Owner(s)

Novartis Pharmaceuticals Corp

Mechanism(s) Of Action

Target Name Target Type Action Type Target ChEMBL ID
Tyrosine-protein kinase receptor FLT3 SINGLE PROTEIN INHIBITOR CHEMBL1974
Stem cell growth factor receptor SINGLE PROTEIN INHIBITOR CHEMBL1936
Protein kinase C (PKC) PROTEIN FAMILY INHIBITOR CHEMBL2093867
Platelet-derived growth factor receptor PROTEIN COMPLEX INHIBITOR CHEMBL2095189
Vascular endothelial growth factor receptor 2 SINGLE PROTEIN INHIBITOR CHEMBL279

Unichem Links

SureChEMBL SCHEMBL8295379
DrugBank DB06595
PubChem: Thomson Pharma 14788708 14935507
PubChem 9829523
LINCS LSM-2287
Nikkaji J1.312.230J
PDBe 2K2
BindingDB 50326053
DrugCentral 5231
Brenda 216818 146800
ChemicalBook CB71315281
Guide to Pharmacology 5702
rxnorm RYDAPT MIDOSTAURIN
PubChem: Drugs of the Future 22395186
ChEBI 63452
ZINC ZINC000100013130